Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery by Heller, Axel R. et al.
Impact of n-3 fatty acid supplemented parenteral nutrition on
haemostasis patterns after major abdominal surgery
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In various diseases n-3 fatty acids exert anti-inflammatory properties. These effects seem to be
related to the uptake and incorporation of eicosapentaenoic acid (EPA) into the cellular substrate
pool after dietary intake of EPA, which is contained in fish oils (FO). In the state of inflammation
EPA is released to compete with arachidonic acid (AA) for metabolism at the cyclo-oxygenase
and the 5-lipoxygenase level. The metabolites of EPA have less inflammatory and chemotactic
potency than the substances derived from AA. In addition to positive effects, early studies
pointed towards prolonged bleeding times after dietary intake of n-3 fatty acids. This study was
undertaken to address the issue of potential coagulation disturbances associated with
postoperative parenteral FO administration. This was a prospective, randomised, double blinded
clinical trial, carried out in two operative intensive care units (13 and 16 beds) in a university
hospital. Forty-four patients undergoing elective major abdominal surgery participated in the
trial. Patients were randomly assigned to receive total parenteral nutrition (TPN) supplemented
with either soybean oil (SO, Lipovenoesw 10 % PLR; 1:0 g/kgBW per day; n ¼ 20) for five days
or with a combination of FO and SO (FO, Omegavenw; 0:2 g/kgBW per day plus SO,
Lipovenoesw 10 % PLR; 0:8 g/kgBW per day, n ¼ 24), respectively. Blood samples were taken
preoperatively (day 21), prior to (day 1) during (days 2–5) and after TPN (day 6). The
coagulation parameters thromboplastin time (Quick), activated partial thromboplastin time
(aPTT), fibrinogen and antithrombin III were measured. To differentially assess activation levels
of extrinsic and intrinsic coagulation pathway, factors VIIa and XIIa were quantified. Moreover
platelet function was determined by resonance thrombography. Baseline values of coagulation
and platelet function were comparable in both groups, but coagulation activity dropped after
surgery. Over the observation period of 6 days, however, physiological levels were regained. No
clinically significant differences were observed between the SO2 and SO 1 FO2 group. These
findings suggest that infusion of fish oil in doses up to 0:2 g/kgBW per day is safe regarding
coagulation and platelet function.
n-3 Fatty acids: Fish oil: Haemostasis: Coagulation
Introduction
After the epidemiological studies of Dyerberg & Bang, in
which it has been shown, that Eskimos have a lower
incidence of thrombosis, coronary heart disease and
myocardial infarction, interest was focused on n-3
polyunsaturated fatty acids (n-3 PUFA) (Dyerberg et al.
1975, 1978, 1979). Compared with the European control
group, the content of n-3 PUFA (contained in fish-oil,
FO), especially of cis 5,8,11,14,17-eicosapentaenoic acid
(EPA) was increased in thrombocytes of Eskimos. Since
then, numerous studies in vitro, as well as in vivo have
been carried out, which showed anti-inflammatory
properties of n-3 PUFA (Leaf, 1990) in various diseases,
such as coronary heart disease (Burr et al. 1989), burns
(Alexander & Gottschlich, 1990) severe multiple trauma
(Bastian et al. 1998) and acute respiratory distress
(ARDS; Gadeck et al. 1999).
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n-3 PUFA are capable of preventing hyperinflammatory
processes by cell to cell signal modulation (Grimm et al.
1995). On one hand, the reduced release of pro-
inflammatory arachidonic acid metabolites and platelet
activating factor, and on the other hand, increased formation
of anti- inflammatory n-3 eicosanoids might account for a
n-3 PUFA dependent decrease of tumour necrosis factor a
(Endres et al. 1989) and interleukin (IL) -1 (Molvig et al.
1991) production by monocytes. In previous studies we
demonstrated a decreased inflammatory pulmonary vascular
response due to FO-infusion. Blunted lung oedema
formation was observed due to reduced pulmonary vascular
resistance and permeability (Koch et al. 1993, 1995; Breil
et al. 1996). After studies demonstrating improved survival
following cecal ligation and puncture in FO supplemented
rats (Johnson et al. 1993) neutrophils from septic patients
stimulated ex vivo generated an altered lipid mediator
spectrum reflecting the n-3 content of the administered fatty
acid emulsions. Moreover pro-inflammatory cytokine levels
were decreased (Grimminger, 1995). Beneficial effects of
FO on pulmonary vasculature as postulated by our group
(Koch et al. 1993, 1995; Breil et al. 1996) were confirmed in
a recent publication (Gadeck et al. 1999) in 146 patients
with ARDS. Due to improvement of pulmonary gas
exchange as indicated by augmentation of the PaO2/FiO2
ratio, lower levels of FiO22 and positive endexspiratory
pressure (PEEP) were required for an adequate oxygenation.
Accordingly the number of respirator free days was
increased under n-3 PUFA supplementation and intensive
care unit (ICU)- stay was shortened (Gadeck et al. 1999).
Compared with European controls, decreased levels of
myocardial infarction in Greenland Eskimos, as observed in
early epidemiological studies (Dyerberg et al. 1975, 1978,
1979) were attributed to an increase in bleeding time and
changes of platelet aggregation after dietary intake of n-3
PUFA contained in FO. More recent publications, however,
report no (Swails et al. 1993) or only clinically irrelevant
(Rogers et al. 1987) changes in platelet aggregation.
Because of beneficial effects on the outcome of severely
ill patients (Bastian et al. 1998; Gadek et al. 1999) and the
controversial issue of haemostasis during n-3 PUFA
administration (Knapp, 1997) the current study was
designed to investigate whether supplementation of total
parenteral nutrition (TPN) with FO affects platelet function
and plasma haemostatic factors in patients after elective
major gastrointestinal surgery. Differential effects on
intrinsic and extrinsic activation of the coagulation system




With institutional review board approval and patient written
informed consent, forty-four patients suffering from
carcinoma of the gastrointestinal tract or pancreas were
prospectively enrolled. Elective surgery (Table 1) was
performed between May 1999 and February 2000. Post-
operatively the patients were observed for 5 days either in
the thirteen bed intensive care unit (ICU) of the Department
of Anaesthesiology or in the sixteen bed surgical ICU. All
patients were postoperatively extubated, spontaneously
breathing and received TPN for 5 days. After inclusion in
this study, the patients were randomly assigned to receive
either TPN supplementation with SO or TPN supplemen-
tation with SO 1 FO (Table 2). Inclusion of patients to the
Table 1. Demographic characteristics, mean (SD)
Patients SO ðn ¼ 20Þ SO 1 FO ðn ¼ 24Þ P
Age (y) 60:8 (10:9) 61:0 (12:6) 0:96
Gender (male/female) 14/6 18/6 1:00
SAPS II at entrya 12:0 (5:2) 12:4 (5:2) 0:80
Body mass index 24:5 (4:1) 25:2 (4:4) 0:56




Whipple procedure 8 10
Total colectomy 1 0
a Simplified Acute Physiology Score II (Le Gall et al. 1993).
Table 2. Composition of the lipid emulsions
Lipovenoesw 10 % PLR
(g/l) Refined soy bean oil
(SO)
Omegavenw 10 %
(g/l) Refined fish oil
(FO)
EPA C20 : 5 n-3 – 12:5–28:2
DHA C22 : 6 n-3 – 14:4–30:9
Myristic acid C14 : 0 0:06 1:0–6:0
Palmitic acid C16 : 0 12:00 2:5–10:0
Palmitoleic acid C16 : 1 n-7 – 3:0–9:0
Stearic acid C18 : 0 4:00 0:5–2:0
Oleic acid C18 : 1 n-9 22:42 6:0–13:0
Linoleic acid C18 : 2 n-6 46:1–55:7 1:0–7:0
Linolenic acid C18 : 3 n-3 4:8–10:6 #2:0
Stearidonic acid C18 : 4 n-3 – 0:5–4:0
Eicosaenoic acid C20 : 1 n-9 – 0:5–3:0
Arachidonic acid C20 : 4 n-6 – 1:0–4:0
Docosaenoic acid C22 : 1 n-9 – #1:5
DPA C22 : 5 n-3 – 1:5–4:5
Other fatty acids – 10:51
A. R. Heller et al.S96
 
  
            
          
 
 
    
                  
                                                                    
                
                                
 
 
    
                    
                              
       
respective groups was achieved by computer derived block
randomisation. Solutions were prepared in the central
pharmacy of the university hospital, delivered blinded to the
ICU, and further handled by a nurse who was unaware of the
study protocol. The investigators were, thus, blinded to
the infused drug. On the preoperative day (day 21)
baseline values were obtained and again on the first
postoperative day (day 1), before TPN was started.
Interventions
All patients received TPN for 5 days postoperatively
according to Table 3 by an indwelling central venous 3
lumen catheter. Glucose (Glucosteril 40 %, Fresenius-Kabi,
Bad Homburg, Germany), amino acids (Aminosteril 10 %,
Fresenius-Kabi) and a soybean oil emulsion (Lipovenoesw
10 % PLR, Fresenius-Kabi) were provided to both groups by
means of infusion pumps (Volumed mVP5000, Fresenius-
Kabi, Bad Homburg, Germany). In the FO-group, however,
the n-6 lipid content of TPN was partially replaced by n-3
PUFA (Omegavenw, Fresenius-Kabi) up to 0:2 g/kgBW
per day, which is the maximum recommended daily
Omegavenw dosage. Moreover all patients daily received
fat- (Vitalipid, Pharmacia, Erlangen, Germany) and water
soluble vitamins (Soluvit, Pharmacia) as well as trace
elements (Addel N, Pharmacia).
Blood samples
In addition to the routine laboratory measurements,
including peripheral blood cell counts and biochemical
analysis, 2 ml of citrated whole blood were obtained at
08:00 daily for resonance thrombography. Plasma for
analysis of the coagulation factors VIIa and XIIa was
separated and kept deep frozen at 2808C until
measurement.
Routine coagulation parameters
The coagulation parameters thromboplastin time (Quick),
activated partial thromboplastin time (aPTT), fibrinogen,
antithrombin (AT) III and platelet counts were quantified in
the Department of Clinical Chemistry, University Hospital
of Dresden, Germany, according to standard procedures.
Reference values were: Quick (70–120 %), aPTT
(30–40 s), fibrinogen (1:5–4:6 g/l), AT III (80–120 %)
and platelet counts (150–400 GPt/l).
Factor VIIa
A test kit (Staclot VIIa-rTF, Diagnostica Stago, Parsippany,
NJ, USA) for the determination of activated Factor VII in
citrated plasma was used according to the manufacturers
specifications. The recombinant soluble tissue factor (rsTF)
holds a cofactor function specific for factor VIIa, in the
presence of factor VIIa, phospholipids and Ca11 the rsTF
initiates coagulation of plasma. In this system the observed
clotting time bears an inverse relationship with the factor
VIIa level initially present in the plasma being tested. The
rsTF does not activate factor VII into factor VIIa;
consequently the factor VII present in the test plasma does
not interfere in the assay.
Factor XIIa
For the quantitative detection of activated factor XII in
plasma an immunoassay (Progen Biotechnik, Heidelberg,
Germany) was used according to the manufacturer’s
specifications. The wells of the XIIa microtiter strips are
coated with mouse monoclonal antibodies specific for XIIa.
During the first incubation XIIa will bind to the immobilised
antibody. After removal of unbound plasma components, a
conjugate of enzyme labelled polyclonal sheep antihuman
XIIa antibody binds to surface bound antigen. Following
development with substrate solution absorbance is
measured at 550 nm. Reference values for healthy
volunteers: 1:7–2:3 ng/ml.
Resonance thrombography (RTG)
RTG was performed with an RTG-analyser (CS-3,
Amelung, Lemgo, Germany) according to the manufac-
turer’s specifications from 250ml of citrated whole blood to
which 150ml of CaCl2 (25 mmol/l) were added. Coagu-
lation is mechanically activated in whole blood according to
physiological conditions of blood current and intravascular
shear stress. Measuring coagulation on the basis of the
resonance effect induced by the elastic fibrin structure the
RTG principle (Hartert, 1981) is different from thromb-
elastographs (Mischke, 2000). Information about velocity
and quality of clot formation is given by a specific graph.
Distinct segments of the RTG plot represent fibrin formation
( f-time=duration of upward slope) or platelet function
( p-time=duration of downward slope). RTG p-time reflects
functionality of platelet derived coagulation, regardless of
the underlying cause of platelet malfunction (low platelets,
uraemia, fibrinogen cleavage products).
Table 3. Regimen of total parenteral nutrition







(Lipovenoesw 10 % PLR)
Lipids (Lipovenoesw 10 % PLR)
(Omegavenw 10 %)
1 2:0 g/kg per d 0:5 g/kg per d 0:8 g SO/kg per d 0:64 g SO/kg per d
10:16 g FO/kg per d
2–5 3:0 g/kg per d 1:2 g/kg per d 1:0 g SO/kg per d 0:8 g SO/kg per d
10:2 g FO/kg per d
n-3 Fatty acids and coagulation S97
 
  
            
          
 
 
    
                  
                                                                    
                
                                
 
 
    
                    
                              
       
Statistics
Data are presented as arithmetic mean (SD). Differences of
single measurements between groups were tested with
Student’s t-test or Chi square test. Repeated measurement
analysis within and between groups was achieved with
general linear model (GLM). Pre TPN values were
considered as covariates during statistical analysis. Signifi-
cance was accepted at P,0:05. Analysis was performed
using SPSS for MS Windows (Release 10.0.7, SPSS,
Chicago, IL).
Results
Clinical characteristics of the patients
Demographic characteristics of the patients concerning age,
gender, SAPS II (Le Gall et al. 1993) at entry, body mass
index and surgical procedures are summarised in Table 1.
There were no significant differences between groups at
entry.
Standard coagulation parameters
Baseline values of Quick [SO: 103(15 %) v. SO 1 FO
102(10 %)] and aPTT [SO: 33(4 s) v. SO 1 FO: 33(4 s)]
before surgery did not differ significantly between the two
groups. Surgery significantly (P,0:001) reduced Quick
[SO: 70(14 %) v. SO 1 FO: 72(8 %)] and increased aPTT
[SO: 47(10 s) v. SO 1 FO: 44(7 s)]. Over time there were no
significant differences between groups and baseline values
were regained between days 3 and 4 after surgery. During
this time daily heparin administration (Liquemin, Roche,
Grenzach-Whylen, Germany) was adjusted to achieve aPTT
between 35 and 40 s. The required dosages of heparin were
comparable in both groups and increased from day 1 [SO:
10278(3627) I.U. v. SO 1 FO: 10104(4163) I.U.] to day 6
[SO: 14583(2745) I.U. v. SO 1 FO: 13542(3825) I.U.].
Cumulative fluid balance over the 5 postoperative days did
not differ significantly [SO: 14729(3340 ml) v. SO 1 FO:
14201(3368 ml); P¼0:39]. Postoperative levels of
fibrinogen [SO: 2:3 (0:6 g/l) v. SO 1 FO: 2:2 (0:6 g/l)] and
AT III [SO: 64(12 %) v. SO 1 FO: 61(12 %)] as well as
measurements until day 6 of fibrinogen [SO: 5:5(1:3 g/l) v.
SO 1 FO: 6:2(1:7 g/l)] and AT III [SO: 86(14 %) v.
SO 1 FO: 85(18 %)] revealed no significant between-
group differences.
Activated factors VII and XII
Factor VIIa dependent clotting time [(Fig. 1) preoperative:
SO: 42(13 s) v. SO 1 FO: 49(19 s)] dropped postoperatively
[day 1: SO: 28(9 s) v. SO 1 FO: 34(14 s)] but preoperative
values were regained on day 3. Levels of factor XIIa [(Fig. 2)
preoperative: SO: 2:0 (0:6 ng/ml) v. SO 1 FO: 2:2
(1:0 ng/ml)] declined to a minimum on postoperative day
3 [SO: 1:4 (0:6 ng/ml) v. SO 1 FO: 1:6 (0:6 ng/ml)].
Concentrations of both factor VIIa and factor XIIa were not
significantly different between groups.
Platelet function
Platelet counts [preoperative: SO: 232(87 GPt/l) v.
SO 1 FO: 224(112 GPt/l)] dropped during surgery [SO:
185(59 GPt/l) v. SO 1 FO: 179(123 GPt/l)] but regained
baseline values at postoperative day 4 [SO: 205(62 GPt/l) v.
SO 1 FO: 214(78 GPt/l)]. Platelet function (Fig. 3) as
observed by RTG- p-time [preoperative: SO: 2:2(1:1 min) v.
SO 1 FO: 2:6(2:4 min)] was delayed postoperatively
[SO: 3:6(2:2 min) v. SO 1 FO: 4:1(2:9 min)]. At day 3
preoperative levels of platelet function were re-established.
No differences in platelet counts or function were found
between groups.
Complications
Bleeding complications were comparably low in both
groups. Preoperatively measured haemoglobin concen-
trations [SO: 7:4(1:2 mmol/l) v. SO 1 FO: 7:9(1:6 mmol/l)]
mmol/l)] declined during surgery [SO: 7:2(1:1 mmol/l) v.
Fig. 1. Factor VIIa induced clotting time [s, mean (SD)] after major
abdominal surgery followed by total parenteral nutrition (TPN)
supplemented with soybean oil (K) or with SO 1 fish oil (W). No
statistical significant between-group difference could be detected.
Fig. 2. Activated factor XII levels [mean ng/ml (SD)] after major
abdominal surgery followed by total parenteral nutrition (TPN)
supplemented with soybean oil (K) or with SO 1 fish oil (W). No
statistical significant between-group difference could be detected
(GLM).
A. R. Heller et al.S98
 
  
            
          
 
 
    
                  
                                                                    
                
                                
 
 
    
                    
                              
       
SO 1 FO: 6:6(1:1 mmol/l)]. Minimum values were reached
at day 3 [SO: 6:3(0:6 mmol/l) v. SO 1 FO: 6:0
(0:9 mmol/l)]. GLM-analysis revealed no differences
between the groups (P¼0:41). Postoperatively transfused
amounts of packed red blood cells [SO: 317(787 ml) v.
SO 1 FO: 325(405 ml)] showed no difference between SO
and SO 1 FO groups. Administration of fresh frozen plasma
(FFP) during TPN, however, was more frequent in the SO
group [156(311 ml)] compared with SO 1 FO [42(167 ml)]
but the difference did not reach statistical significance
(P¼0:17). Mean total hydroxyethyl starch 10 % 250/0:5
administration was higher in the SO 1 FO group
[3458(1565 ml) v. SO: 2750(1328 ml)], but no level of
significance was reached.
Discussion
During the past decades intensive collaborative research in
the fields of chronic and acute inflammatory disorders has
resulted in a better understanding of the pathophysiology
and diagnosis of these diseases. In the early phase of
inflammation interleukins and lipid-mediators are exces-
sively released and play a crucial role in the pathogenesis of
organ dysfunction (Heller et al. 1998). Arachidonic acid
(AA) is the precursor of the pro-inflammatory eicosanoids,
and is released from membrane phospholipids in the course
of inflammatory activation and subsequently metabolized to
prostaglandins and leukotrienes. Various strategies have
been evaluated to control the excessive production of lipid
mediators, such as inhibition of phospholipase A2, the
enzyme catalysing AA release, the blockade of cyclo-
oxygenase- and lipoxygenase enzymes as well as the
development of receptor antagonists against platelet
activating factor and leukotrienes.
Encouraging results on a variety of outcome parameters
were obtained in critically ill patients by supplementation
with long chain n-3 fatty acids, as part of an enteral nutrition
regimen (Bower et al. 1995; Bastian et al. 1998; Gadeck
et al. 1999). In states of inflammation, EPA is released to
compete with AA for metabolism inducing the production
of less inflammatory and less chemotactic derivatives.
Because n-3 PUFA containing lipid emulsions are now
available for intravenous administration to humans, the
current study was designed to address the controversial
subject of haemostasis (Rogers et al. 1987; Swails et al.
1993; Knapp, 1997) during the maximum recommended FO
dosage (0:2 g/kg per day) in terms of plasmatic haemostasis
and platelet function after major abdominal surgery. The
setting of surgical trauma and TPN was chosen to assure
intravascular availability of the fatty acids, which could not
be guaranteed in the situation of enteral nutrition in which
gastrointestinal transport and mucosal uptake function could
confound measured parameters.
In this study patients undergoing major abdominal
surgery were enrolled. The two groups were comparable
regarding standard demographic characteristics and surgical
trauma (Table 1). Classical haemostasis parameters such as
Quick, aPTT, platelet counts and AT III were measured
prior to surgery and before start of TPN at postoperative day
1. These values varied as expected after a major abdominal
surgical procedure, indicating a moderate activation of
coagulation, without significant differences between the two
study groups. During the postoperative observation period,
however, preoperative coagulation capacity was regained
regardless of the type of PUFA administered.
While n-3 PUFA modulate cytokine expression (Endres
et al. 1989; Molvig et al. 1991; Chandrasekar & Fernandes,
1994) PUFA-dependent effects on tissue factor (TF)
expression and the extrinsic coagulation pathway were
further differentiated by means of quantification of activated
factor VII. When TF is presented to plasma components
during vascular injury, extrinsic coagulation is activated.
Factor VIIa and its cofactor TF assemble on a negatively
charged membrane surface in a Ca21-dependent manner to
form an enzyme complex which proteolytically converts
factor X to Xa (Bach, 1988). As depicted in Fig. 1 surgical
trauma accelerates factor VIIa-induced clotting, reflecting
an elevated level of activated factor VII and a postoperative
(day 1) hypercoagulatory extrinsic state. Fish oil adminis-
tration at the concentration used in this study, however, does
not seem to interfere with TF/VIIa activation.
The influence of fatty acid administration on intrinsic
coagulation were investigated by measurement of activated
factor XII (Fig. 2), which is a component of the contact
system of blood coagulation which also includes prekallik-
rein, HMW kininogen and factor XI. Because the main
physiological activators of factor XII include fatty acids and
the surface of certain types of lipoprotein particles
(Mitropoulos et al. 1989), analysis of factor XIIa during
differential PUFA administration was of special interest. In
contrast to the effect on extrinsic factor VIIa, surgical
trauma was of minor influence for intrinsic factor XIIa
levels. Moreover, differential PUFA administration had no
impact on XIIa formation.
As expected no differences in platelet counts were
observed among the study groups. Platelet function,
however, as analysed by RTG did not differ either (Fig. 3).
Reduced levels of platelet activating factor (PAF) due to n-3
PUFA, as reported by Sperling et al. (1987) might, thus, be
of minor impact in the current clinical setting. Postoperative
Fig. 3. Downward slope period (min) in resonance thrombography
(RTG)¼platelet induced clot retraction ( p)-time [mean (SD)], after
major abdominal surgery followed by total parenteral nutrition (TPN)
supplemented soybean oil (K) or with SO 1 fish oil (W). No
statistical significant between-group difference could be detected.
n-3 Fatty acids and coagulation S99
 
  
            
          
 
 
    
                  
                                                                    
                
                                
 
 
    
                    
                              
       
delay in RTG p-time might reflect dilution effects due to
intravenous fluids.
Global parameters for the estimation of the quality of
coagulation and haemostasis such as haemoglobin levels or
the demand for packed red blood cells were in accordance to
coagulation parameter measurement and were independent
of differential PUFA administration. The underlying cause
for insignificant higher need of fresh frozen plasma in the
SO-group cannot be answered from the laboratory
measurements and might reflect physician decisions being
based upon the individual clinical aspect, rather than on
laboratory values. The mean total amount of hydroxyethyl
starch was insignificantly higher in the SO 1 FO-group. A
more extensive intraoperative administration of hydroxy-
ethyl starch solution which accounted for that difference had
minor impact on coagulation.
Summarising our results, fish oil administered up to
0:2 g/kg per day, was shown to be safe in terms of intrinsic
and extrinsic coagulation and did not influence platelet
aggregation. Regarding the beneficial effects in critically ill
patients, attributed to n-3 PUFA, which are covered by a
variety of studies, enteral or parenteral nutrition with
these nutrients should be considered as a part of anti-
inflammatory immunonutrition.
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